A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NBL-012 in Healthy Chinese Subjects
Latest Information Update: 05 May 2023
Price :
$35 *
At a glance
- Drugs NBL-012 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors NovaRock Biotherapeutics
- 04 May 2023 Results published in the NovaRock Biotherapeutics Media Release
- 19 Jul 2022 Status changed from active, no longer recruiting to completed.
- 17 Feb 2022 Status changed from planning to active, no longer recruiting.